Compare CPA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPA | LEGN |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.9B |
| IPO Year | 2005 | 2020 |
| Metric | CPA | LEGN |
|---|---|---|
| Price | $120.67 | $27.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $159.80 | $72.92 |
| AVG Volume (30 Days) | 319.4K | ★ 1.8M |
| Earning Date | 11-19-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 6.63 | N/A |
| EPS | ★ 16.07 | N/A |
| Revenue | ★ $3,533,554,000.00 | $909,045,000.00 |
| Revenue This Year | $6.00 | $68.68 |
| Revenue Next Year | $9.14 | $48.49 |
| P/E Ratio | $7.55 | ★ N/A |
| Revenue Growth | 1.53 | ★ 74.75 |
| 52 Week Low | $82.54 | $25.71 |
| 52 Week High | $130.00 | $45.30 |
| Indicator | CPA | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 38.87 |
| Support Level | $118.07 | $26.43 |
| Resistance Level | $122.21 | $29.39 |
| Average True Range (ATR) | 3.82 | 1.30 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 55.38 | 30.00 |
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.